Corpus Intelligence IC Memo — LLANO MEMORIAL HOSPITAL 2026-04-26 12:34 UTC
IC Memo — LLANO MEMORIAL HOSPITAL
Investment Committee Memorandum | TX | 25 beds | Grade D | EBITDA uplift $153K
🛡️ Public data only — no PHI permitted on this instance.
Investment Committee Memorandum

LLANO MEMORIAL HOSPITAL

CCN 450219 | LLANO, TX | 25 beds | April 26, 2026
EBITDA BridgeData Room
D
Investability

1. Target Overview & Investment Thesis

LLANO MEMORIAL HOSPITAL is a 25-bed community hospital in LLANO, TX with $1.9M in net patient revenue and a -70.9% operating margin. The hospital serves a payer mix of 53.1% Medicare, 0.0% Medicaid, and 46.9% commercial.

Thesis: Turnaround. Our ML models identify $153K in annual EBITDA improvement potential from RCM optimization across 5 levers, lifting margin from -70.9% to -62.7% (+820bps).

Net Revenue HCRIS$1.9M
Current EBITDA COMPUTED$-1.3M
Operating Margin COMPUTED-70.9%
Occupancy HCRIS2.1%
Revenue / Bed COMPUTED$75K
Net-to-Gross HCRIS20.6%
Distress Probability MLnan%

2. Market Context & Competitive Position

583
TX Hospitals
-0.7%
State Median Margin
256
Comparable Hospitals

TX has 583 Medicare-certified hospitals with a median operating margin of -0.7%. The target's margin of -70.9% places it below the state median. Among 256 size-comparable peers (12-50 beds), the median margin is -7.9%. The target's below-peer margin suggests operational improvement opportunity.

3. RCM Performance Analysis — Comparable Hospitals

Comps selected by bed count (12-50), prioritizing same-state peers. 256 hospitals in the comp set.

HospitalStateBedsRevenueMargin
LLANO MEMORIAL HOSPITAL (Target)TX25$1.9M-70.9%
WISE HEALTH SYSTEM - PARKWAYTX36$361.0M-15.5%
CORYELL MEMORIAL HOSPITALTX25$305.9M-1.5%
TEXAS ORTHOPEDIC HOSPITATX42$237.8M46.3%
METHODIST HOSPITAL FOR SURGERYTX32$178.4M22.8%
TEXAS SPINE AND JOINT HOSPITALTX20$147.3M30.3%
NORTH CENTRAL SURGICAL HOSPITATX24$143.6M32.0%
SCOTT AND WHITE HOSPITAL TAYLOTX25$139.7M-47.5%
BAYLOR SURGICAL HOSPITAL AT FOTX30$136.0M14.8%

4. Predicted Improvement Opportunities

Improvement targets set at P75 of comparable peers with 60% gap closure assumption. Coefficients calibrated to published research bands. Total EBITDA uplift: $153K (820bps margin improvement).

LeverCurrentTargetEBITDA ImpactMarginRamp
Denial Rate Reduction12.0%6.5%$44K+237bp12mo
Net Collection Rate93.5%97.0%$39K+210bp18mo
Cost to Collect4.5%2.5%$37K+200bp12mo
A/R Days Reduction5200.0%3800.0%$23K+122bp9mo
Clean Claim Rate88.0%96.0%$10K+51bp6mo

5. EBITDA Bridge

Denial Rate Reduction
$44K
Net Collection Rate
$39K
Cost to Collect
$37K
A/R Days Reduction
$23K
Clean Claim Rate
$10K
Total EBITDA Uplift$153K
Current EBITDA$-1.3M
+ RCM Uplift+$153K
Pro Forma EBITDA$-1.2M
Current Margin-70.9%
Pro Forma Margin-62.7%
WC Released (1x)$72K

6. Returns Analysis — Scenario Matrix

5-year hold, 5.5x leverage, 3% organic growth, 10%/yr debt paydown. Base case uses 100% of predicted RCM uplift. Bull case: 130% uplift at lower entry. Bear case: 50% uplift at higher entry.

ScenarioEntryExitEquity InEquity OutMOICIRR
Base Case10.0x10.0x$-2.0M$-7.2M0.00x-100.0%
Base (11x exit)10.0x11.0x$-2.0M$-8.6M0.00x-100.0%
Bull Case9.0x11.0x$-1.8M$-8.7M0.00x-100.0%
Bull (12x exit)9.0x12.0x$-1.8M$-10.1M0.00x-100.0%
Bear Case11.0x10.0x$-2.2M$-7.3M0.00x-100.0%
Bear (11x exit)11.0x11.0x$-2.2M$-8.8M0.00x-100.0%

7. Key Risks & Mitigants

SeverityRisk FactorMitigant
HighNegative operating marginRCM uplift bridge shows clear path to profitability; working capital release provides near-term cash cushion
MediumLow occupancyAt 2.1%, fixed costs are spread over fewer patient days. Mitigant: volume growth is an additional upside lever not modeled in base case

8. Data Sources & Methodology Appendix

Data Sources

  • CMS HCRIS Cost Reports (Medicare-certified hospitals)
  • CMS Medicare Utilization (DRG-level volumes)
  • CMS Chronic Conditions (county-level disease prevalence)
  • HCRIS multi-year trend data (financial time series)

Comparable Selection

  • 256 hospitals with 12-50 beds
  • Same-state prioritization (n=257)
  • Comp margins: P25=-36.4% / P50=-7.9% / P75=9.6%

Bridge Methodology

  • Targets: P75 of comparable peers (60% gap closure)
  • Denial: avoidable share = 35% of delta × NPR
  • AR: bad debt coefficient = $0.65 per day per $1K NPR
  • NCR: 60% coefficient on collection rate improvement
  • CDI: 0.75% of Medicare revenue per 0.01 CMI point

Returns Assumptions

  • Leverage: 5.5x entry (84.6% debt / 15.4% equity)
  • Organic growth: 3% annual EBITDA growth
  • Debt paydown: 10% of principal per year
  • Hold period: 5 years

Generated by SeekingChartis on April 26, 2026. All predictions use public data only. Confidence intervals calibrated via split conformal prediction (90% coverage target). This memo is for informational purposes and does not constitute investment advice.